삼성서울병원

Ko En

혈액종양내과 윤상은 교수

진료분야
림프종, 악성림프종, 조혈모세포이식, 다발성 골수종
진료일정 12 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
오전
오후
진료일정 01 月
날짜
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
오전
오후

학력

학력
2020.02 이화여자대학교 의학과 대학원 박사졸업
2012.02 이화여자대학교 의학전문대학원 석사학위 취득

경력

경력
2019.03 ~현재 삼성서울병원 혈액종앙내과 임상조교수
2018.03 ~ 2019.02 삼성서울병원 혈액종양내과 임상강사
2017.03 ~ 2018.02 이대목동병원 혈액종양내과 임상강사
2013.03 ~ 2017.02 이대목동병원 레지던트
2012.03 ~ 2013.02 이대목동병원 인턴

학회활동

학회활동
2018.08 ~ 현재 대한암학회 정회원
2017.08 ~ 현재 대한혈액학회 정회원
2013.03 ~ 현재 대한내과학회 정회원
  • J NEUROIMMUNOL 2021 10.1016/j.jneuroim.2021.577564 Increased proportion of CD20+T cells after rituximab treatment in patient with neuromyelitis optica later diagnosed with lung B-cell lymphoma: A case report Lee1, JK; Kwon, S; Han, JH; Yoon, SE; Kim, BJ; Kang, ES
    View PubMed
  • KOREAN J INTERN MED 2021 10.3904/kjim.2019.367 Real-world data on the survival outcome of patients with newly diagnosed Waldenstrom macroglobulinemia Cho1, JH; Shim, JH; Yoon, SE; Kim, HJ; Kim, SH; Ko, YH; Lee, ST; Kim, K; Kim, WS; Kim, SJ
    View PubMed
  • CANCER MANAG RES 2021 10.2147/CMAR.S309092 Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma Lee1, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ
    View PubMed
  • EXP HEMATOL ONCOL 2021 10.1186/s40164-021-00224-3 Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas Yoon1, SE; Cho, J; Kim, YJ; Ko, YH; Park, WY; Kim, SJ; Kim, WS
    View PubMed
  • FRONT ONCOL 2021 10.3389/fonc.2021.628807 Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Lee1, B; Lee, H; Cho, J; Yoon, SE; Kim, SJ; Park, WY; Kim, WS; Ko, YH
    View PubMed
  • SCI REP-UK 2021 10.1038/s41598-021-85332-0 Metabolic activity of extranodal NK/T cell lymphoma on F-18-FDG PET/CT according to immune subtyping Lim1, CH; Yoon, SE; Kim, SJ; Cho, J; Ko, YH; Lee, KH; Kim, WS
    View PubMed
  • J CANCER 2021 10.7150/jca.55553 Exosomal miR-1305 in the oncogenic activity of hypoxic multiple myeloma cells: a biomarker for predicting prognosis Lee1, JY; Ryu, D; Lim, SW; Ryu, KJ; Choi, ME; Yoon, SE; Kim, K; Park, C; Kim, SJ
    View PubMed
  • J CANCER 2021 10.7150/jca.54434 Impact of transformation on the survival of patients diagnosed with follicular lymphoma that progressed within 24 months Yoon1, SE; Cho, J; Kim, WS; Kim, SJ
    View PubMed
  • J HEPATOL 2021 10.1016/j.jhep.2020.08.010 Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma Kim1, CG; Kim, C; Yoon, SE; Kim, KH; Choi, SJ; Kang, B; Kim, HR; Park, SH; Shin, EC; Kim, YY; Kim, DJ; Chung, HC; Chon, HJ; Choi, HJ; Lim, HY
    View PubMed
  • CANCERS 2020 10.3390/cancers12123548 Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma Ryu1, KJ; Lee, JY; Choi, ME; Yoon, SE; Cho, J; Ko, YH; Shim, JH; Kim, WS; Park, C; Kim, SJ
    View PubMed
  • BLOOD ADV 2020 10.1182/bloodadvances.2020002814 A risk model for relapsed/refractory aggressive NHL integrating clinical risk factors and pretransplant Deauville score Yhim1, HY; Eshet, Y; Metser, U; Lim, CH; Lajkosz, K; Isaev, K; Cooper, M; Prica, A; Kukreti, V; Bhella, S; Lang, N; Lee, KH; Xu, W; Hodgson, D; Tsang, R; Yoon, SE; Kim, SJ; Kim, WS; Crump, M; Kuruvilla, J; Kridel, R
    View PubMed
  • BLOOD 2020 10.1182/blood.2020005026 Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma Kim1, H; Jeong, H; Yamaguchi, M; Sohn, I; Yoon, SE; Byeon, S; Hur, JY; Koh, Y; Yoon, SS; Kim, EJ; Oguchi, M; Miyazaki, K; Taguchi, S; Yoon, DH; Cho, J; Ko, YH; Kim, SJ; Suzuki, R; Kim, WS
    View PubMed
  • BMC CANCER 2020 10.1186/s12885-020-07317-y Endothelial activation and stress index (EASIX) is a reliable predictor for overall survival in patients with multiple myeloma Song1, GY; Jung, SH; Kim, K; Kim, SJ; Yoon, SE; Lee, HS; Kim, M; Ahn, SY; Ahn, JS; Yang, DH; Kim, HJ; Lee, JJ
    View PubMed
  • SCI REP-UK 2020 10.1038/s41598-020-68310-w Prognostic significance of interim PET/CT response for the treatment of advanced-stage marginal zone lymphoma in the post-rituximab era Song1, GY; Yoon, SE; Kim, SJ; Kim, JS; Koh, Y; Moon, JH; Oh, SY; Lee, HS; Shin, HJ; Do, YR; Lee, WS; Kim, DS; Park, Y; Yhim, HY; Yang, DH
    View PubMed
  • KOREAN JOURNAL OF INTERNAL MEDICINE 2020 10.3904/kjim.2018.396 Asian variant of intravascular large B-cell lymphoma a comparison of clinical features based on involvement of the central nervous system Yoon1, SE; Kim, WS; Kim, SJ
    View PubMed
  • ANN HEMATOL 2020 10.1007/s00277-020-04005-6 A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis Yoon1, SE; Kim, SJ; Yoon, KH; Koh, Y; Mun, YC; Do, YR; Choi, YS; Yang, DH; Kim, MK; Lee, GW; Suh, C; Ko, YH; Kim, WS
    View PubMed
  • ANN HEMATOL 2020 10.1007/s00277-020-04008-3 Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas Hur1, JY; Kim, YJ; Yoon, SE; Son, DS; Park, WY; Kim, SJ; Park, D; Kim, WS
    View PubMed
  • CYTOKINE 2020 10.1016/j.cyto.2020.155048 Pre-treatment serum IL-10 predicts the risk of secondary central nervous system involvement in patients with diffuse large B-cell lymphoma Yi1, JH; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ
    View PubMed
  • ANN HEMATOL 2020 10.1007/s00277-020-04083-6 A comprehensive analysis of adult patients with secondary hemophagocytic lymphohistiocytosis: a prospective cohort study Yoon1, SE; Eun, Y; Huh, K; Chung, CR; Yoo, IY; Cho, J; Cho, D; Ko, YH; Park, S; Kim, WS; Kim, SJ
    View PubMed
  • MODERN PATHOL 2020 10.1038/s41379-019-0392-8 Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression Cho1, J; Kim, SJ; Park, WY; Kim, J; Woo, J; Kim, G; Yoon, SE; Ko, YH; Kim, WS
    View PubMed
  • PSYCHO-ONCOL 2020 10.1002/pon.5265 Impact of fear of cancer recurrence on survival among lymphoma patients Kim1, SJ; Kang, D; Kim, IR; Yoon, SE; Kim, WS; Butow, PN; Guallar, E; Cho, J
    View PubMed
  • BMC CANCER 2020 10.1186/s12885-020-6612-2 Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma Cho1, I; Lee, H; Yoon, SE; Ryu, KJ; Ko, YH; Kim, WS; Kim, SJ
    View PubMed
  • J Cancer 2019 10.7150/jca.30355 The impact of primary tumor site on outcomes of treatment with etoposide and cisplatin in grade 3 gastroenteropancreatic neuroendocrine carcinoma Yoon1, SE; Kim, JH; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed
  • BMC UROL 2019 10.1186/s12894-019-0463-7 A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naive prostate cancer Yoon1, SE; Kim, Y; Cho, J; Kang, M; Sung, HH; Jeon, HG; Jeong, BC; Seo, SI; Jeon, SS; Lee, HM; Choi, HY; Lee, SJ; Park, SH
    View PubMed
  • J Cancer 2019 10.7150/jca.29106 The Impact of Primary Tumor Sidedness on the Effect of Regorafenib in Refractory Metastatic Colorectal Cancer Yoon1, SE; Lee, SJ; Lee, J; Park, SH; Park, JO; Lim, HY; Kang, WK; Park, YS; Kim, ST
    View PubMed

해당하는 결과가 없습니다.